Amy C. Peterson, M.D. has been appointed chief medical officer, Immuno-oncology at BeiGene, Ltd.  Dr. Peterson will lead the global clinical development of BGB-A317, BeiGene’s PD-1 inhibitor, and BGB-290, a PARP inhibitor, as well as its pipeline of other immuno-oncology agents. Dr. Eric Hedrick, currently serving as the interim chief medical officer, will continue to oversee global clinical hematology development including the program for BGB-3111, BeiGene’s BTK inhibitor, and will remain serving as an advisor.
 
Dr. Peterson joins the company from Medivation, where she was vice president of Clinical Development responsible for the development of enzalutamide and talazoparib in breast cancer and of pidilizumab in diffuse large b-cell lymphoma. Previously, she served as associate group medical director at Genentech, where she was responsible for the development of early stage molecules targeting multiple major pathways in oncology.
 
“We are delighted to have Dr. Peterson join our team,” said John V. Oyler, founder, chief executive officer, and chairman of BeiGene. “BeiGene continues to expand its senior medical leadership in response to emerging global development opportunities, particularly in immuno-oncology. Amy’s broad experience in oncology drug development and her academic background in immuno-oncology research are well-suited to our expanding clinical development efforts. We very much look forward to her contribution in the continued growth and development of our existing and future pipeline and the company as a whole.”